Table 3.
Main outcome variables
| Outcome | Propensity-matched groups | Relative risk (95% CIa) | Absolute risk increase (95% CI) | Pb | |
|---|---|---|---|---|---|
| Control n = 237 | RBCcn = 237 | ||||
| 90-day mortality | 80 (34) | 102 (43) | 1.28 (1.01–1.61) | 9.3% (0.6–18%) | 0.032 |
| 180-day mortality | 91 (38) | 116 (49) | 1.27 (1.04–1.57) | 11% (1.7–19%) | 0.018 |
| RRTd | 21 (8.9) | 48 (20) | 2.29 (1.41–3.69) | 11% (5.1–18%) | 0.001 |
| AKIN | 0 (0–2) | 0 (0–3) | 0.001 | ||
| DAFe of RRT | 28 (16–28) | 28 (9–28) | 0.29 | ||
| DAF of vasopressors | 26 (13–27) | 23 (7–26) | 0.009 | ||
| DAF of mechanical ventilation | 26 (12–28) | 21 (4–27) | 0.002 | ||
| SOFA maxf | 9 (7–12) | 11 (8–13) | < 0.001 | ||
Data are presented as number (%) or median (interquartile range)
aConfidence interval
bWilcoxon rank sum or McNemar´s test
cLow-grade red blood cell transfusion defined as < 670 ml any of the first 5 days
dRenal Replacement Therapy
eDays Alive and Free
fSequential Organ Failure Assessment score the first 10 days after admission